LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: SKI-1/S1P Facilitates SARS-CoV-2 Spike Induced Cell-to-Cell Fusion via Activation of SREBP-2 and Metalloproteases, Whereas PCSK9 Enhances the Degradation of ACE2.

    Essalmani, Rachid / Andréo, Ursula / Evagelidis, Alexandra / Le Dévéhat, Maïlys / Pereira Ramos, Oscar Henrique / Fruchart Gaillard, Carole / Susan-Resiga, Delia / Cohen, Éric A / Seidah, Nabil G

    Viruses

    2023  Volume 15, Issue 2

    Abstract: Proprotein convertases activate various envelope glycoproteins and participate in cellular entry of many viruses. We recently showed that the convertase furin is critical for the infectivity of SARS-CoV-2, which requires cleavage of its spike protein (S) ...

    Abstract Proprotein convertases activate various envelope glycoproteins and participate in cellular entry of many viruses. We recently showed that the convertase furin is critical for the infectivity of SARS-CoV-2, which requires cleavage of its spike protein (S) at two sites: S1/S2 and S2'. This study investigates the implication of the two cholesterol-regulating convertases SKI-1 and PCSK9 in SARS-CoV-2 entry. The assays used were cell-to-cell fusion in HeLa cells and pseudoparticle entry into Calu-3 cells. SKI-1 increased cell-to-cell fusion by enhancing the activation of SREBP-2, whereas PCSK9 reduced cell-to-cell fusion by promoting the cellular degradation of ACE2. SKI-1 activity led to enhanced S2' formation, which was attributed to increased metalloprotease activity as a response to enhanced cholesterol levels via activated SREBP-2. However, high metalloprotease activity resulted in the shedding of S2' into a new C-terminal fragment (S2″), leading to reduced cell-to-cell fusion. Indeed, S-mutants that increase S2″ formation abolished S2' and cell-to-cell fusion, as well as pseudoparticle entry, indicating that the formation of S2″ prevents SARS-CoV-2 cell-to-cell fusion and entry. We next demonstrated that PCSK9 enhanced the cellular degradation of ACE2, thereby reducing cell-to-cell fusion. However, different from the LDLR, a canonical target of PCSK9, the C-terminal CHRD domain of PCSK9 is dispensable for the PCSK9-induced degradation of ACE2. Molecular modeling suggested the binding of ACE2 to the Pro/Catalytic domains of mature PCSK9. Thus, both cholesterol-regulating convertases SKI-1 and PCSK9 can modulate SARS-CoV-2 entry via two independent mechanisms.
    MeSH term(s) Humans ; Angiotensin-Converting Enzyme 2 ; Cell Fusion ; COVID-19 ; HeLa Cells ; Metalloproteases ; Proprotein Convertase 9/genetics ; SARS-CoV-2 ; Sterol Regulatory Element Binding Protein 1
    Chemical Substances Angiotensin-Converting Enzyme 2 (EC 3.4.17.23) ; Metalloproteases (EC 3.4.-) ; PCSK9 protein, human (EC 3.4.21.-) ; Proprotein Convertase 9 (EC 3.4.21.-) ; Sterol Regulatory Element Binding Protein 1 ; membrane-bound transcription factor peptidase, site 1 (EC 3.4.21.112)
    Language English
    Publishing date 2023-01-27
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2516098-9
    ISSN 1999-4915 ; 1999-4915
    ISSN (online) 1999-4915
    ISSN 1999-4915
    DOI 10.3390/v15020360
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: Functional regulation of LDLR levels.

    Fruchart Gaillard, Carole / Ouadda, Ali Ben Djoudi / Ciccone, Lidia / Girard, Emmanuelle / Mikaeeli, Sepideh / Evagelidis, Alexandra / Le Dévéhat, Maïlys / Susan-Resiga, Delia / Lajeunesse, Evelyne Cassar / Nozach, Hervé / Ramos, Oscar Henrique Pereira / Thureau, Aurélien / Legrand, Pierre / Prat, Annik / Dive, Vincent / Seidah, Nabil G

    Molecular metabolism

    2022  Volume 67, Page(s) 101662

    Abstract: Objective: The liver-derived circulating PCSK9 enhances the degradation of the LDL receptor (LDLR) in endosomes/lysosomes. PCSK9 inhibition or silencing is presently used in clinics worldwide to reduce LDL-cholesterol, resulting in lower incidence of ... ...

    Abstract Objective: The liver-derived circulating PCSK9 enhances the degradation of the LDL receptor (LDLR) in endosomes/lysosomes. PCSK9 inhibition or silencing is presently used in clinics worldwide to reduce LDL-cholesterol, resulting in lower incidence of cardiovascular disease and possibly cancer/metastasis. The mechanism by which the PCSK9-LDLR complex is sorted to degradation compartments is not fully understood. We previously suggested that out of the three M1, M2 and M3 subdomains of the C-terminal Cys/His-rich-domain (CHRD) of PCSK9, only M2 is critical for the activity of extracellular of PCSK9 on cell surface LDLR. This likely implicates the binding of M2 to an unknown membrane-associated "protein X" that would escort the complex to endosomes/lysosomes for degradation. We reported that a nanobody P1.40 binds the M1 and M3 domains of the CHRD and inhibits the function of PCSK9. It was also reported that the cytosolic adenylyl cyclase-associated protein 1 (CAP1) could bind M1 and M3 subdomains and enhance the activity of PCSK9. In this study, we determined the 3-dimensional structure of the CHRD-P1.40 complex to understand the intricate interplay between P1.40, CAP1 and PCSK9 and how they regulate LDLR degradation.
    Methods: X-ray diffraction of the CHRD-P1.40 complex was analyzed with a 2.2 Å resolution. The affinity and interaction of PCSK9 or CHRD with P1.40 or CAP1 was analyzed by atomic modeling, site-directed mutagenesis, bio-layer interferometry, expression in hepatic cell lines and immunocytochemistry to monitor LDLR degradation. The CHRD-P1.40 interaction was further analyzed by deep mutational scanning and binding assays to validate the role of predicted critical residues. Conformational changes and atomic models were obtained by small angle X-ray scattering (SAXS).
    Results: We demonstrate that PCSK9 exists in a closed or open conformation and that P1.40 favors the latter by binding key residues in the M1 and M3 subdomains of the CHRD. Our data show that CAP1 is well secreted by hepatic cells and binds extracellular PCSK9 at distinct residues in the M1 and M3 modules and in the acidic prodomain. CAP1 stabilizes the closed conformation of PCSK9 and prevents P1.40 binding. However, CAP1 siRNA only partially inhibited PCSK9 activity on the LDLR. By modeling the previously reported interaction between M2 and an R-X-E motif in HLA-C, we identified Glu
    Conclusions: The present study reveals that CAP1 enhances the function of PCSK9, likely by twisting the protein into a closed configuration that exposes the M2 subdomain needed for targeting the PCSK9-LDLR complex to degradation compartments. We hypothesize that "protein X", which is expected to guide the LDLR-PCSK9-CAP1 complex to these compartments after endocytosis into clathrin-coated vesicles, is HLA-C or a similar MHC-I family member. This conclusion is supported by the PCSK9 natural loss-of-function Q554E and gain-of-function H553R M2 variants, whose consequences are anticipated by our modeling.
    MeSH term(s) Proprotein Convertase 9/genetics ; Proprotein Convertase 9/metabolism ; HLA-C Antigens ; Serine Endopeptidases/metabolism ; Proprotein Convertases/genetics ; Proprotein Convertases/metabolism ; Scattering, Small Angle ; X-Ray Diffraction ; Receptors, LDL/metabolism
    Chemical Substances PCSK9 protein, human (EC 3.4.21.-) ; Proprotein Convertase 9 (EC 3.4.21.-) ; HLA-C Antigens ; Serine Endopeptidases (EC 3.4.21.-) ; Proprotein Convertases (EC 3.4.21.-) ; CAP1-6D ; Receptors, LDL
    Language English
    Publishing date 2022-12-22
    Publishing country Germany
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2708735-9
    ISSN 2212-8778 ; 2212-8778
    ISSN (online) 2212-8778
    ISSN 2212-8778
    DOI 10.1016/j.molmet.2022.101662
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: PCSK7: A novel regulator of apolipoprotein B and a potential target against non-alcoholic fatty liver disease.

    Sachan, Vatsal / Le Dévéhat, Maïlys / Roubtsova, Anna / Essalmani, Rachid / Laurendeau, Jean-Francois / Garçon, Damien / Susan-Resiga, Delia / Duval, Stéphanie / Mikaeeli, Sahar / Hamelin, Josée / Evagelidis, Alexandra / Chong, Michael / Paré, Guillaume / Chernetsova, Elizabeta / Gao, Zu-Hua / Robillard, Isabelle / Ruiz, Matthieu / Trinh, Vincent Quoc-Huy / Estall, Jennifer L /
    Faraj, May / Austin, Richard C / Sauvageau, Martin / Prat, Annik / Kiss, Robert S / Seidah, Nabil G

    Metabolism: clinical and experimental

    2023  Volume 150, Page(s) 155736

    Abstract: Background: Epidemiological evidence links the proprotein convertase subtilisin/kexin 7 (PCSK7) to triglyceride (TG) metabolism. We associated the known PCSK7 gain-of-function non-coding SNP rs236918 with higher levels of plasma apolipoprotein B (apoB) ... ...

    Abstract Background: Epidemiological evidence links the proprotein convertase subtilisin/kexin 7 (PCSK7) to triglyceride (TG) metabolism. We associated the known PCSK7 gain-of-function non-coding SNP rs236918 with higher levels of plasma apolipoprotein B (apoB) and the loss-of-function coding variant p.Pro777Leu (SNP rs201598301) with lower apoB and TG. Herein, we aimed to unravel the in vivo role of liver PCSK7.
    Methods: We biochemically defined the functional role of PCSK7 in lipid metabolism using hepatic cell lines and Pcsk7
    Results: Independent of its proteolytic activity, membrane-bound PCSK7 binds apoB100 in the endoplasmic reticulum and enhances its secretion. Mechanistically, the loss of PCSK7/Pcsk7 leads to apoB100 degradation, triggering an unfolded protein response, autophagy, and β-oxidation, eventually reducing lipid accumulation in hepatocytes. Non-alcoholic fatty liver disease (NAFLD) was induced by a 12-week high fat/fructose/cholesterol diet in wild type (WT) and Pcsk7
    Conclusions: Our data reveal hepatic PCSK7 as one of the major regulators of apoB, and its absence reduces apoB secretion from hepatocytes favoring its ubiquitination and degradation by the proteasome. This results in a cascade of events, eventually reducing hepatic lipid accumulation, thus supporting the notion of silencing PCSK7 mRNA in hepatocytes for targeting NAFLD.
    MeSH term(s) Mice ; Animals ; Non-alcoholic Fatty Liver Disease/genetics ; Non-alcoholic Fatty Liver Disease/metabolism ; Subtilisin/metabolism ; Triglycerides/metabolism ; Liver/metabolism ; Apolipoproteins B/genetics ; Apolipoproteins B/metabolism ; Proprotein Convertases/metabolism ; Apolipoprotein B-100/genetics ; Apolipoprotein B-100/metabolism
    Chemical Substances Subtilisin (EC 3.4.21.62) ; Triglycerides ; Apolipoproteins B ; Proprotein Convertases (EC 3.4.21.-) ; Apolipoprotein B-100
    Language English
    Publishing date 2023-11-13
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80230-x
    ISSN 1532-8600 ; 0026-0495
    ISSN (online) 1532-8600
    ISSN 0026-0495
    DOI 10.1016/j.metabol.2023.155736
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top